Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526185 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
A Early Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT03526185 is a Early Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 6 participants.
The verdict
NCT03526185, a Early Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
To determine the feasibility and safety of administering a regimen of TIL/IL-2, using a cell product manufactured in the Yale Advanced Cell Therapy Laboratories, in subjects with metastatic melanoma who are not responding or have progressed after receiving prior therapy with a PD-1/PD-L1 antagonist used alone or in combination with anti-CTLA-4. Additionally, a second cohort of patients with metastatic melanoma who are not responding or have progressed after receiving prior therapy with a PD-1/PD-L1 antagonist alone or in combination with anti-CTLA-4 will receive anti-PD-1 and anti-CTLA-4 therapy with Nivolumab and Ipilimumab.
Interventions
- DRUG Tumor Infiltrating Lymphocytes
- DRUG Nivolumab and Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2020-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03526185
The ClinicalTrials.gov registry entry for NCT03526185 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tumor Infiltrating Lymphocytes is the first listed.
NCT03526185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03526185 about?
NCT03526185 is a clinical study titled "A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes". To determine the feasibility and safety of administering a regimen of TIL/IL-2, using a cell product manufactured in the Yale Advanced Cell Therapy Laboratories, in subjects with metastatic melanoma who are not responding or have progressed after receiving prior therapy with a PD-1/PD-L1 antagonist ...
What is the current status of trial NCT03526185?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2018-02-06. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT03526185?
The interventions under investigation include: Tumor Infiltrating Lymphocytes (DRUG), Nivolumab and Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03526185?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.